CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid

BACKGROUND: Clinical trials designed to test the efficacy of retinoic acid (RA) as an adjuvant for the treatment of solid cancers have been disappointing, primarily due to RA resistance. Estrogen receptor (ER)-negative breast cancer cells are more resistant to RA than ER-positive cells. The expressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Rong-Zong, Garcia, Elizabeth, Glubrecht, Darryl D., Poon, Ho Yin, Mackey, John R., Godbout, Roseline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491424/
https://www.ncbi.nlm.nih.gov/pubmed/26142905
http://dx.doi.org/10.1186/s12943-015-0380-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491424/
https://www.ncbi.nlm.nih.gov/pubmed/26142905
http://dx.doi.org/10.1186/s12943-015-0380-7

Ejemplares similares